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Background: Synthesis and apoenzyme attachment of lipoic acid have emerged as a new complex metabolic
pathway. Mutations in several genes involved in the lipoic acid de novo pathway have recently been described
(i.e., LIAS, NFU1, BOLA3, IBA57), but no mutation was found so far in genes involved in the specific process of
attachment of lipoic acid to apoenzymes pyruvate dehydrogenase (PDHc), α−ketoglutarate dehydrogenase
(α-KGDHc) and branched chain α-keto acid dehydrogenase (BCKDHc) complexes.
Methods: Exome capture was performed in a boy who developed Leigh disease following a gastroenteritis and
had combined PDH and α-KGDH deficiency with a unique amino acid profile that partly ressembled E3 subunit
(dihydrolipoamide dehydrogenase / DLD) deficiency. Functional studies on patient fibroblasts were performed.
Lipoic acid administration was tested on the LIPT1 ortholog lip3 deletion strain yeast and on patient fibroblasts.
Results: Exome sequencing identified two heterozygous mutations (c.875C > G and c.535A > G) in the LIPT1 gene
that encodes a mitochondrial lipoyltransferase which is thought to catalyze the attachment of lipoic acid on PDHc,
α-KGDHc, and BCKDHc. Anti-lipoic acid antibodies revealed absent expression of PDH E2, BCKDH E2 and α-KGDH E2
subunits. Accordingly, the production of 14CO2 by patient fibroblasts after incubation with
14Cglucose, 14Cbutyrate or
14C3OHbutyrate was very low compared to controls. cDNA transfection experiments on patient fibroblasts rescued
PDH and α-KGDH activities and normalized the levels of pyruvate and 3OHbutyrate in cell supernatants. The yeast
lip3 deletion strain showed improved growth on ethanol medium after lipoic acid supplementation and incubation
of the patient fibroblasts with lipoic acid decreased lactate level in cell supernatants.
Conclusion: We report here a putative case of impaired free or H protein-derived lipoic acid attachment due to
LIPT1 mutations as a cause of PDH and α-KGDH deficiencies. Our study calls for renewed efforts to understand the
mechanisms of pathology of lipoic acid-related defects and their heterogeneous biochemical expression, in order
to devise efficient diagnostic procedures and possible therapies.
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Pyruvate dehydrogenase complex (PDHc) deficiency most
often occurs as an isolated enzyme defect caused by muta-
tions in X-linked PDHA1 [MIM 300502] and associates
with a spectrum of clinical presentations ranging from fatal
infantile lactic acidosis to mild psychomotor retardation
and/or Leigh disease [1]. A smaller number of PDHc defi-
cient individuals have mutations in PDHB, PDHX, dihydro-
lipoyl transacetylase (DLAT), dihydrolipoyl dehydrogenase
(DLD), or PDP1, which is responsible for the reactivation
of phosphorylated PDHc [1]. Lipoic acid is a sulphur-
containing cofactor covalently attached to the PDHc E2
subunit (DLAT) and is functionally required. A defect of
lipoic acid metabolism is expected to affect PDHc as well
as the other key enzymatic complexes that have similar
structure and are lipoic acid dependent, notably α-
ketoglutarate dehydrogenase (α-KGDH), branched chain
keto acid dehydrogenase (BCKDH) and the glycine cleavage
system [2,3].
Two pathways lead to attachment of lipoic acid to apoen-
zymes in bacteria. In the endogenous or de novo pathway,
biosynthesis of lipoic acid follows mitochondrial fatty acid
synthesis (FASII) and iron sulphur cluster biosynthesis. The
first lipoic acid specific enzyme of this pathway is a lipoyl
(octanoyl)transferase which catalyzes the attachment of
octanoate to specific lysyl residues in lipoate-dependent
enzymes (bacterial LipB and likely LIPT2 in humans). The
second enzyme involved is lipoic acid synthase (LipA in
bacteria and LIAS in humans), which catalyzes the conver-
sion of the octanoyl side chain to an active lipoyl. The en-
zyme is an iron sulphur protein with two [4Fe-4S] clusters
[4]. The [4Fe-4S] cluster is a cofactor of LIAS as well as of
many proteins involved in intermediary metabolism and oxi-
dative phosphorylation, where it participates in electron
transfer reactions and in the functions of complexes I, II and
III [5]. Assembly of the [4Fe-4S] cluster involves a complex
metabolic pathway that includes NFU1 (NFU Iron-Sulfur
cluster scaffold homolog), ISCU (Iron-Sulfur cluster scaffold
homolog) and BOLA3 [3] (bolA homolog 3).
The exogenous or salvage pathway involves attachment
of free lipoic acid to the specific lysine residues of the target
proteins. It is still unclear to which degree the lipoic acid
salvage pathway (LplA in bacteria) is conserved in humans,
as the LplA orthologous gene, LIPT1, encodes a lipoyl
transferase that uses free AMP-activated lipoic acid as a
substrate, yet in yeasts, the LIPT1 orthologue lip3 may act
downstream, rather than independently of the de novo
pathway [6,7] (see Discussion). LIPT1 is organized into four
exons in humans, only one of which is coding, and maps to
chromosome 2q11.2.
As yet, mutations have been described in genes in-
volved in the de novo pathway, i.e., NFU1, BOLA3,
LIAS and IBA57 [2,3,8-11]. Here we describe a new
lipoate-related disease that involves impaired lipoateattachment on PDHc and α-KGDH and is due to
LIPT1 mutations.
Methods
This work has been approved by our institutional ethical
committee after declaration to the Département de la
Recherche Clinique et du Développement; informed
consent was obtained from the parents.
Biochemical analysis and respiratory chain investigation
PDH and αKGDH activities, E3 activity, polarographic
and spectrophotometric assay of mitochondrial respira-
tory chain (MRC) complex activities were measured in
leukocytes and skin fibroblasts according to standard
procedures [12,13].
Lactate and pyruvate levels were determined in fibro-
blast supernatants by enzymatic methods.
Oxidation rates of butyrate (fatty acid), 3hydoxybutyrate
(ketone body) and glucose, three main energetic substrates
were measured in cultured patient-derived fibroblasts after
incubation with 1 and 10 mmol/l 1-14C labeled substrates
[1]. The 13C6-labeled leucine loading test was a modification
of a previously described radioactive assay [14] with an
isovaleryl-CoA derivative (3-hydroxyisovaleric acid) as the
readout for BCKDH activity. We used stable isotope (13C6)
labeled leucine as substrate (Eurisotop, Saint-Aubin, France),
and measured the ratio between 3-hydroxyisovaleric acid
stable isotope to natural ions after leucine loading by gas
chromatography – mass spectrometry (300MS from Varian/
Brüker Daltonics, Fremont, CA, USA).
Molecular investigations
DNA was extracted from white blood cells, collected
from the patient and her parents after informed consent.
The known genes PDHA1, PDHB, PDHX, DLAT, DLD
[1], LIAS (GenBank NG_032111.1), BOLA3 (GenBank
NG_031910) and NFU1 (GenBank NG_031931.1) were
directly sequenced using DNA extracted from white
blood cells and intronic primers (purchased from
Applied Biosystems, Forster City, CA).
Exome capture was performed with the SureSelect Hu-
man All Exon 50 Mb kit (Agilent Technologies) with
SOLiD5500 (Life Technologies). 75 + 35 Paired-end reads
were mapped on human genome reference (hg19 build)
using LifeScope (Life Technologies). Filtering was
performed with GATK tools and an in-house software
(PolyWeb).
Immunoblot analysis in LIPT1, NFU1 and PDHA1 mutant
fibroblasts
Total protein extracts were prepared by lysing cultured fi-
broblasts generated from either control individual or from
patients with either LIPT1, NFU1, or PDHA1 mutations.
Cell pellets were lysed in Triton X-100 lysis buffer (50 mM
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EDTA, 40 mM glycerophosphate, 1 mM Na orthovanadate,
10-4 M PMSF, 10-6 M leupeptin, 10-6 M pepstatin A and
1% Triton X-100). 40 μg of total protein extracts were sepa-
rated by SDS-polyacrylamide-gel electrophoresis and trans-
ferred to nitrocellulose membranes, blocked in TBS
containing 5% nonfat milk for 1 hour at room temperature
and incubated overnight at 4°C with primary antibodies.
The following antibodies were used: anti-LIPT1 (Santa
Cruz Biotechnology), anti-lipoic acid (Abcam) to identify
the lipoate containing subunits of oxo acid dehydrogenases
(PDHc, α-KGDHc and BCKDHc) in fibroblasts, anti-
Pyruvate Dehydrogenase E1-α subunit (Abcam) and anti-α
Tubulin (Sigma-Aldrich). Quantitative analyses of immuno-
blots were performed with the Odyssey infrared image sys-
tem (LiCor) using DyLight™ 800 conjugated secondary
antibodies from LiCor.
Patient fibroblast: LIPT1 transfection and lipoic acid
supplementation in the medium
Human fibroblasts from skin biopsies from a control indi-
vidual and the patient were cultured in monolayer flasks
with HamF10 medium containing 12% fetal calf serum
and 100 UI/mL penicillin G and 100 μg/mL streptomycin.
The flasks were incubated at 37°C with 5% carbon
dioxide. Fibroblasts were transfected using pLenti-
GIII-CMV-hLIPT1-HA vector (Applied Biological Material),
and analysed after 36 h.
Control and patient fibroblasts were cultured with culture
medium supplemented with lipoic acid (Sigma) to a final
concentration of 10 and 100 μM. Biochemical investiga-
tions were analysed on cultured skin fibroblasts before and
after three weeks of supplementation.
Yeast model
Wild-type and Δlip3 strains, deleted for LIP3, the gene
orthologous to human LIPT1 [15], were grown on glucose
and ethanol medium for 3 and 7 days at 28°C and 36°C.
Lipoic acid (2 ng/mL) was added in growth medium of
Δlip3 cells to test its potential therapeutic effect.
Results
Clinical phenotype
The patient, a boy, was the first child of non-consanguineous
French parents. He was born at term after an uneventful
pregnancy and spontaneous delivery with normal birth
parameters. Psychomotor development was delayed and
associated with hypotonia. At age 15 months, when the
patient was referred to our unit, metabolic investigations
were regarded as normal, including brain magnetic
resonance imaging (MRI), muscle biopsy, plasma amino
acids and urinary organic acids (data not shown). The
course of the disease was marked by an episode of
metabolic acidosis at 18 months of age that occurredin the context of vomiting and dehydration associated
with gastro-enteritis. The patient had hyperlactatemia
(8 mmol/L), liver cytolysis (AST 305 u/l, ALT 220 u/l,
N < 40) and psychomotor regression that occurred
suddenly and included severe trunk hypotonia, coma
with dystonia and no head control. After a few days,
he was bed- and wheel-chair bound, could not stand
or sit unaided. Severe spastic tetraparesis and extrapyram-
idal syndrome were observed. He could not speak but
understood simple orders. He was otherwise fully con-
scious, alert, and he could smile, laugh and follow with eyes.
Major swallowing difficulties led to gastrostomy. Brain MRI
revealed cerebellar atrophy, an important sus-tentorial
cortical atrophy with ventricular dilatation, bilateral
thalamic anomalies, bi-frontal white matter anomalies
and delayed myelinisation (Additional file 1: Figure S1).
During the decompensation, the MRS spectroscopy with
long TE (144) showed a peak of lactate (Additional file 1:
Figure S1).
Biochemical parameters
The most striking biochemical features involved the plasma
amino acid profile that associated increased levels of glu-
tamine and proline at presentation as well as on repeated
sampling, and low levels of lysine at presentation (Table 1).
This profile was consistent with multiple α-keto acid
dehydrogenase deficiency, particularly involving PDH and
α-KGDH, thus suggestive of E3 subunit/DLD deficiency.
However, no or only slight elevations were noted for
glutamate, α-amino, α-hydroxy or α-ketoadipic acids, thus
contrasting with the large increases and sometimes massive
amounts observed in typical forms of NFU1 deficiency ([2]
and data not shown). In addition, in sharp contrast to all
previously reported patients with deficiency in the de
novo lipoic acid synthesis pathway, in our patient glycine
was not increased in CSF, plasma or urine (Table 1).
This was not consistent with deficiency of the glycine
cleavage system. Furthermore, the branched chain
amino acids unexpectedly showed from very low to
low-normal levels, thus not suggestive of BCKDH defi-
ciency (Table 1).
Mild metabolic acidosis (bicarbonates 16 mmol/L, N >
20 mmol/L) associated with increased level of lactate
and pyruvate in blood (lactate 8 mmol/L, N < 2, pyruvate
0.44 mmol/L, N < 0.2), in urine (lactate 252 μmol/mmol
of creatinine) and CSF (lactate 6.60 mmol/L, pyruvate
0.36 mmol/L). Urinary α-ketoglutarate was highly in-
creased (Table 1). On subsequent tests, lactate and pyru-
vate levels as well as urinary α-ketoglutarate were
normalized.
A severe decrease of PDH and α-KGDH activities was
found in patient fibroblasts (Table 2), and BCKDH activity
was also strongly reduced, as inferred by a 13C6 labeled
leucine loading test that showed levels comparable
Table 1 Relevant plasma, urinary and CSF amino acids
and urinary organic acid levels
At presentation Patient follow-up
through age 4 years(age 18 months)
Plasma
(μmol/L) Patient
Reference
interval
Patient Patient
Median Range
Glutamate 119 2 - 118 97.5 60 – 241
Glutamine 1228 334 - 666 820 615 – 1381
Proline 441 61 - 285 417.5 179 – 576
Glycine 144 149 - 301 263.5 144 – 356
Alanine 470 134 - 502 455 221 – 1086
Valine 64 158 - 310 128 32 – 155
Isoleucine 21 37 - 89 39.5 7 – 51
Leucine 45 68 - 168 67.5 15 – 76
Lysine 52 113 - 269 180.5 142 – 326
CSF (μmol/L)
Glutamate 0 ND
Glutamine 723 352 - 885
Glycine 5 1 - 16
Alanine 52 6 - 47
Urine (μmol/mmol of
creatinine)
Glutamate 2 <11
Glutamine 603 62 - 165
Glycine 229 110 - 356
Alanine 239 41 - 130
α-ketoglutarate 6224 <79
Llactate 252 <52
Succinate 15 <97
Fumarate 48 <7
Reference intervals are provided as the range of the age-matched reference
population. Median and range of plasma amino acid values are also provided
for the patient samples (N = 8) collected during follow-up.
Table 2 Biochemical investigations
Patient Control
Enzyme activities (pmol/min/mg protein)
ketoglutarate dehydrogenase (α-KGDH) 900 7000
Isocitrate dehydrogenase (IDH) 21000 23000
Pyruvate dehydrogenase (PDH) 90 1117
Citrate Synthase (SC) 27000 48000
Polarographic study (nmolO2/min/mg protein)
Pyruvate +malate 6.2 31.1 +/- 2
Malate + glutamate 5.4 28.9 +/- 4.5
CO2 production (nmol/h/mg of protein)
Butyrate 1.5 6
Octanoate 0.9 3.4
Palmitate 1.6 3.5
Glucose (1 mmol/l) 2.8 7.8
Glucose (10 mmol/l) 3.7 8.8
OH butyrate (1 mmol/l) 0.8 3
OH butyrate (10 mmol/l) 2.3 8.5
PDHc, α-KGDHc activities and polarographic studies on patient and control
skin fibroblasts, CO2 production after administration of
14C-3OHbutyrate,
14C-glucose or 14C- butyrate in fibroblasts of the patient and a control.
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In contrast, mitochondrial respiratory chain activities
and E3 subunit (DLD) activity measured in fibroblast
homogenates were normal (data not shown). Polaro-
graphic assay in fibroblasts showed reduced oxygen pro-
duction using pyruvate as substrate (2.2 nmol O2/min/mg
of protein, reference range from 3.3 to 6.8 nmol O2/min/
mg of protein).
Oxidation rates of butyrate (fatty acid), 3-hydroxybutyrate
(ketone body) and glucose were measured by incubating
patient-derived fibroblasts with 1 and 10 mmol/l 1-14C
labeled substrates. We found that CO2 production by the
Krebs cycle and mitochondrial respiratory chain activity in
fibroblast’s patient were very low compared to con-
trols after administration of each of these substrates
(Table 2), suggesting a defect in both the Krebs’ cycle
and PDH.Molecular investigations
To identify the causative gene mutation, we first excluded
the genes PDHA1, PDHB, PDHX, DLAT, DLD [1], LIAS
(GenBank NG_032111.1), BOLA3 (GenBank NG_031910)
and NFU1 (GenBank NG_031931.1) by direct sequencing
using DNA extracted from white blood cells. Subsequently,
exome capture was performed and resulted in a list of 25
candidate genes, including a mitochondrial protein, LIPT1
(MIM 610284). The compound heterozygous c.875C >G
and c.535A >G transitions in LIPT1 gene (NP_660200.1)
on chromosome 2 resulted in a stop mutation (p.Ser292X)
and the substitution of a threonine by an alanine (p.
Thr179Ala) in the protein, respectively. Sanger sequencing
confirmed these mutations in the affected individual and
showed that the parents were heterozygous for either muta-
tion. These changes were predicted to be “damaging” and
“deleterious” by Polyphen and SIFT softwares, respectively,
and were located in a highly conserved domain of the pro-
tein. In addition, these mutations were not found in 100
controls of French origin or in exome sequencing projects
including at least 13 000 alleles [http://evs.gs.washington.
edu/EVS/].
Immunoblotting
A LIPT1 antibody failed to detect the LIPT1 protein in
patient fibroblasts (Figure 1A). Anti-lipoate antibody failed
to detect the expected lipoylated proteins of ketoacid dehy-
drogenases (PDHc, α-KGDHc and BCKDHc) in the patient
fibroblasts as well as in fibroblasts of another patient with
NFU1 mutations, whereas normal bands were seen in
Figure 1 Western blots of patient fibroblasts with antibodies against LIPT1 (A), lipoic acid (B), and tubulin (Sigma-Aldrich) or actine in
cultures in basal conditions (A, B) and after LIPT1 transfection (C). A and B: Control, patients (P) with PDHA1, NFU1 and LIPT1 mutations were
as indicated. A: the LIPT1 antibody failed to detect the LIPT1 protein in patient fibroblasts. B: Anti-lipoate antibody failed to detect the expected
lipoylated proteins of ketoacid dehydrogenases (PDHc, α-KGDHc and BCKDHc) in the patient fibroblasts as well as in fibroblasts of another patient
with NFU1 mutations, whereas normal bands were seen in patient fibroblasts with PDHA1 mutations and in control. C: Control (C), Patient with
LIPT1 mutations (P), patient fibroblasts transfected with LIPT1 (P + LIPT1). Anti-lipoate antibody revealed normalized and very moderately increased
amounts of BCKDH (x8) and α-KGDH (x1.8) proteins, respectively, in patient fibroblasts after LIPT1 transfection whereas no band was detected for
PDH protein.
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(Figure 1B). By contrast anti PDH E1-α (Abcam) antibody
detected normal bands in the LIPT1-mutated patient fibro-
blasts (data not shown).LIPT1 transfection
Control and patient fibroblasts were transfected using the
pLenti-GIII-CMV-hLIPT1-HA vector and analyzed after
36 h. As shown in Figure 1C after LIPT1 transfection, anti-
lipoate antibody revealed normalized (×8) and moderately
(×1.8) increased amounts of BCKDH and α-KGDH pro-
teins, respectively, in patient fibroblasts (quantification was
performed with image J software) whereas no band was de-
tected for PDH protein. PDH and α-KGDH activities in-
creased moderately after LIPT1 transfection (PDH: 90 and
93 to 210 and 215 pmoles/min/mg protein; α-KGDH: 0.9
to 3 nmoles/min/mg protein). Lactate (L) and pyruvate (P)
levels were significantly increased in fibroblast supernatantscompared to controls and they were dramatically decreased
after LIPT1 transfection (Figure 2A-B). Interestingly, the
level of 3OHbutyrate also decreased with a concomitant
increase of glucose suggesting that the cells metabolized
3OHbutyrate upon partial rescue of α-KGDH activity
(Figure 2C-D).Lipoic acid administration on yeast model and human
fibroblasts
Wild-type and Δlip3 strains, deleted for lip3, the gene
orthologous to human LIPT1 [15], were grown on
glucose and ethanol medium for 3 and 7 days at 28°C
and 36°C. A growth defect of Δlip3 cells on ethanol
was observed at 28°C and was exacerbated at 36°C
(Figure 3A).
Lipoic acid (2 ng/mL) was added in growth medium of
Δlip3 cells to test its potential therapeutic effect and it
markedly improved Δlip3 growth (Figure 3A).
Figure 2 Levels of lactate (A), pyruvate (B), glucose (C) and 3OHbutyrate (D) in supernatants from patient fibroblast’s cultured in basal
condition and after LIPT1 transfection. P: patient, C: control. A-B: Lactate (L) and pyruvate (P) levels were significantly increased in fibroblast
supernatants compared to controls and they were dramatically decreased after LIPT1 transfection. C-D: the level of 3OHbutyrate also decreased
with a concomitant increase of glucose suggesting that the cells metabolized 3OHbutyrate upon partial rescue of α-KGDH activity. Data are
represented as mean ± SEM.
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tures were supplemented with lipoic acid to a final concen-
tration of 10 or 100 μM during three weeks. In the patient
fibroblasts, this led to absent, or only moderate increase
of αKGDH and PDH activities respectively (Figure 3B),
yet lactate level decreased significantly and this effect
contrasted with the lactate increase observed in control
fibroblasts (Figure 3C). Nevertheless, the 13C6-labeled leucine
loading test showed no effect of lipoic acid on BCKDH acti-
vity (Figure 3D). Thus, lipoic acid supplementation might
have beneficial, though only partial effects, through mecha-
nism(s) that remain to be determined.
Discussion
We describe here a novel disease mechanism involving
lipoic acid in humans that is induced by mutations invol-
ving the LIPT1 gene. This increases the spectrum of the
lipoic acid defects beyond those recently implicated in the
de novo biosynthesis of lipoic acid, which include LIAS and
the ancillary iron sulfur [Fe-S] cluster pathway (see above).
We show that LIPT1 mutations reduce lipoylation of PDHc
and α-KGDHc, and result in severely decreased PDHc and
α-KGDHc enzyme activities and abnormal pyruvate
utilization by polarography.
Based on available evidence [6,7], impaired attachment of
non-protein bound, AMP-activated lipoic acid on mito-
chondrial proteins (thus affecting a putative lipoic acid“salvage” pathway) might be responsible for PDH and
α-KGDH deficiencies in this patient. However, free lipoic
acid does not seem to be able to compensate for other de-
fects in the lipoylation pathway in yeast and mouse
[5,11,15], whereas we show that it can partly rescue the
growth of yeasts deficient for the LIPT1 orthologue. Pos-
sible mechanisms are presented in Figure 4, which shows on
the top, the putative salvage pathway of free AMP-activated
lipoic acid, and on the bottom, an alternative or complemen-
tary mechanism with LIPT1 that redistributes lipoyl residues
from the E2 subunit (H protein) of glycine cleavage system
to the other complexes (as proposed in yeast [15]). In this
mechanism, the original de novo pathway that involves
LIPT2 and LIAS would act only on the H protein. Other
mechanisms, such as partial redundancy between LIPT1
and LIPT2 operating either upstream of LIAS and/or in the
usage of free AMP-lipoic acid as a substrate, cannot be
excluded. None of these mechanisms accounts for the low
branched chain amino acid levels in our patient and the
greater susceptibility to BCKDHc lipoylation rescue of the
patient fibroblasts (Table 1 and Figure 1C), suggesting
that LIPT1 may be differentially required for BCKDHc vs
α−KGDHc and PDHc (see also below).
The most striking biochemical features involved plasma
amino acids that at presentation, associated increased levels
of glutamine, proline with low levels of lysine and branched
amino acids. Because of absent glycine increase, this profile
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Figure 3 Effects of lipoic acid administration on Δlip3-deleted yeast strain and patient fibroblasts. A: Growth of Δlip3 on glucose and
ethanol at different temperature and after lipoic acid administration. Δlip3 yeasts failed to growth on ethanol at 28°C and the effect was stronger
at 36°C. Lipoic acid was added in growth medium of Δlip3 strains and strikingly improved Δlip3 growth (2 ng/ml). B: PDH, α-KGDH and citrate
synthase (CS) activities measured on cultured fibroblasts in basal condition and after administration of lipoic acid. In patient fibroblasts, this led to
absent, or only moderate increase of α-KGDH and PDH activity. C: Lactate levels in cultured fibroblast supernatants in basal condition and after
administration of lipoic acid. P: patient, C: control. Lactate level decreased significantly and this effect contrasted with the increase observed in
control fibroblasts. Data are represented as mean ± SEM. D: Labeled to natural isotopic ratios for 3-hydroxyisovaleric acid (an isovaleryl-CoA
derivative) in the LIPT1-deficient patient compared to a MSUD and control patient. The panel shows that LIPT1 deficiency leads to a severe loss of
metabolic flux involving BCKDH that is similar to BCDKH deficiency. The (+) and (-) signs stand for whether lipoate was added. Y-axis: ratio of
stable isotope labeled vs natural 3-hydroxyvaleric acid. Error bars indicate standard deviations from triplicate experiments.
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DLD deficiency rather than other genes involved in de novo
biosynthesis of lipoic acid such as NFU1, LIAS, IBA57,
BOLA3 (as hyperglycinemia is a hallmark of the associated
biochemical phenotype). Of note, the fact that elevated
glycine (in several biological fluids) was the only observed
amino acid abnormality in these diseases except for NFU1
deficiency, raises the possibility that when de novo lipoate
synthesis is impaired, secondary deficiency of the dehydro-
genase complexes other than the glycine cleavage system
may be compensated for, though only partly, by LIPT1-me-
diated lipoylation. This is consistent with the possibility that
part of LIPT1 action may be independent of LIPT2 and
LIAS, and this may be related to its ability to process free
lipoate (Figure 4). In addition, the profile of our patient
differed from E3 deficiency as branched chain amino acid
levels were unexpectedly very low to low-normal, whereasthey tend to be elevated in E3 deficiency, because of the as-
sociated BCKDH deficiency (which isolated, is responsible
for maple syrup urine disease [16]). We verified that E3 ac-
tivity was normal. Branched chain amino acid levels are
known to be low in presence of BCKDH derepression fol-
lowing BKDK inactivation [17] and also in other conditions
(e.g., nutritional deficiency), but none of these conditions
can readily be reconciled with the proposed mechanisms of
LIPT1 deficiency (Figure 4), as well as with some of our
in vitro studies (Figure 1C), or the overall amino acid pro-
file shown by our patient at diagnosis and throughout
follow-up (Table 1). Tissue specific differences may be in-
volved, because basal BCKDH activity was clearly reduced
in patient fibroblasts (Figure 3D).
Other explanations are possible and these results
should be interpreted in the light that a large pro-
portion of patients with related disorders such as E3
Figure 4 Possible pathways for lipoic acid attachment to
mitochondrial α-ketodehydrogenase apoenzymes.
AMP-activated forms of free lipoic acid could be a source of direct
lipoylation via LIPT1 (the “lipoic acid salvage pathway”). This mechanism
is at odds with some data in mice and yeast, yet it may account
for apparent compensatory effects observed in the human disorders
(see text). Another mechanism proposed in yeasts [15] may involve the
H protein of the glycine cleavage system as a donor of lipoyl redidues
to the other complexes via LIPT1. In this case, the de novo pathway
involving LIPT2 and LIAS would act only on the H protein. This partly
accounts for the different amino acid profiles observed in patients.
The action of LIPT1 on BCKDH may be more complex than for other
dehydrogenases (see text).
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only transient or intermittent biochemical abnormalities
(personal unpublished data), consistent with extensive
heterogeneity of clinical and biochemical features in
these diseases.
Based on our enzyme assays, CO2 production by the
Krebs cycle and mitochondrial respiratory chain activity in
patient fibroblasts were very low compared to controls after
administration of each of three substrates (glucose, butyrate
and 3OHbutyrate), suggesting a defect in both the Krebs’
cycle and PDH. Interestingly, the level of 3OHbutyrate also
increased in fibroblast supernatant, presumably resulting
from decreased α-KGDH activity. Furthermore, 3OHbuty-
rate level decreased with a concomitant increase of glucose
in fibroblast supernatant after LIPT1 transfection, consist-
ent with the possibility that the cells metabolized 3OHbuty-
rate upon partial rescue of α-KGDH activity. The novel
combination of biochemical tests presented here is a pro-
mising tool for Krebs cycle investigations, particularly for
in vitro testing of potential therapeutic applications. From
this test we have been able to infer that candidate dietary
treatments for this metabolic disease, such as ketogenic
diet, were likely detrimental. The argument was very low
CO2 production after administration of
C143OHbutyrate
and C14butyrate.
Contrary to our patient, who had biochemical abnor-
malities restricted to BCKDH, PDH and α-KGDH, thephenotype of the diseases that involve lipoic acid de
novo biosynthesis show numerous additional dysfunc-
tions that are related to the [Fe-S] cluster pathway.
These additional dysfunctions [5,19] affect succinate
dehydrogenase and aconitase, two proteins from the
tricarboxylic acid cycle, as well as the respiratory
chain complexes I-III [5,19]. This may explain why in
these patients, neurological symptoms were associated
with multisystem abnormalities [2,3,8,10,11]. By con-
trast the clinical picture of our patient was limited to
brain thus similar to primary PDH deficiencies. The ex-
treme severity of the neurological defects may result from
the added contribution of α-KGDH deficiency which is ex-
pected to induce a stronger energetic defect compared to
isolated PDH deficiency. Differential tissue-specificity of
LIPT1 function(s) vs the classical de novo lipoylation path-
way might also be involved [20]. However it is of note that
in our patient, biochemical clues expected from an ener-
getic disease such as hyperlactatemia and hyperpyruvice-
mia, or urinary α−ketoglutarate were observed only during
a metabolic attack. This intermittent and moderate bio-
chemical presentation raises the possibility that the disease
may be underdiagnosed. In fact, it was mainly the amino
acid profile, partly suggestive of E3 subunit/DLD-like defi-
ciency (see above), that prompted us to test for deficiency
of α-KGDH and PDH.
A major challenge for this new and severe enzyme
cofactor disease is therapy. A treatment with lipoic acid
may not be indicated as its attachment to enzyme com-
plexes is expected to be impaired in the absence of
LIPT1. However Δlip3 moderately improved growth in
ethanol medium supplemented with lipoic acid, whereas
activity of PDH, but not α-KGDH or BCKDH, moder-
ately increased in patient fibroblasts cultured with lipoic
acid supplementation in the medium. These preliminary
results raise the possibility that lipoic acid may have
therapeutic effects, though moderate and requiring fur-
ther validation.
In conclusion, we report pathogenic LIPT1 gene
mutations in humans, which alter lipoate binding
in PDHc and α-KGDHc, and we provide strong
evidence for the existence of a lipoylation pathway
specific to PDHc and α-KGDHc in humans. This
pathway is at least partly distinct from the de novo
pathway and does not affect lipoylation of the
glycine cleavage complex, as was proposed in yeast
[[15] and Figure 4]. In addition, our data indicate
that LIPT1 deficiency may affect lipoylation of BKCDHc
in a partly unpredicted fashion that remains to be charac-
terized. Further investigations are required to clarify
the complex metabolism of lipoic acid cofactor in
humans, and more efficient procedures should be de-
vised for early diagnosis and prevention of metabolic
decompensations.
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Additional file 1: Figure S1. Brain MRI in the 33 months-old boy with
LIPT1 mutations reveals cerebellar atrophy, an important sus-tentorial
cortical atrophy with ventricular dilatation, bilateral thalamic anomalies,
bi-frontal white matter anomalies and delayed myelinisation on Sagittal
T1 (A), axial T2 (B), and coronal Flair (C). The MRS spectroscopy with long
TE (144) performed at 17 months (during the decompensation) shows a
peak of lactate (D).
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